These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34920802)

  • 1. [Bispecific antibodies targeting CD3 in oncology and hematology].
    Vanacker H; Vinceneux A; Nicolas-Virelizier E; Brahmi M; Cassier PA
    Bull Cancer; 2021 Oct; 108(10S):S181-S194. PubMed ID: 34920802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bispecific antibodies in onco-hematology: Applications and perspectives].
    Barrière S; El-Ghazzi N; Garcia M; Guièze R
    Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bispecific antibodies in multiple myeloma].
    Escure G; Manier S
    Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
    Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
    Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T cell therapy.
    Hosen N
    Immunol Med; 2021 Jun; 44(2):69-73. PubMed ID: 32693699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
    Hays P
    Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
    Nagorsen D; Bargou R; Ruttinger D; Kufer P; Baeuerle PA; Zugmaier G
    Leuk Lymphoma; 2009 Jun; 50(6):886-91. PubMed ID: 19455460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
    Baeuerle PA; Wesche H
    Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current landscape of CD3 bispecific antibodies in hematologic malignancies.
    Kassner J; Abdellatif B; Yamshon S; Monge J; Kaner J
    Trends Cancer; 2024 Aug; 10(8):708-732. PubMed ID: 38987076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
    Riffard C; Teillaud JL
    Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
    Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
    J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forced into battle.
    Kaiser J
    Science; 2020 May; 368(6494):930-933. PubMed ID: 32467373
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
    Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
    Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
    Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
    Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
    Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
    MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cell-Activating Bispecific Antibodies in Cancer Therapy.
    Trabolsi A; Arumov A; Schatz JH
    J Immunol; 2019 Aug; 203(3):585-592. PubMed ID: 31332079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.